Page 28 - GPD-4-1

Gene & Protein in Disease Gene fusions and chimeric RNAs

2021;12:466. 100. Haura EB, Hicks JK, Boyle TA. Erdafitinib overcomes
FGFR3-TACC3-mediated resistance to osimertinib. J Thorac
doi: 10.3390/genes12040466
Oncol. 2020;15(9):e154-e156.
90. Mukherjee S, Detroja R, Balamurali D, et al. Computational
analysis of sense-antisense chimeric transcripts reveals their doi: 10.1016/j.jtho.2019.12.132
potential regulatory features and the landscape of expression 101. Wagner VP, Bingle CD, Bingle L. MYB-NFIB fusion
in human cells. NAR Genom Bioinform. 2021;3(3):lqab074. transcript in adenoid cystic carcinoma: Current state of
knowledge and future directions. Crit Rev Oncol Hematol.
doi: 10.1093/nargab/lqab074
2022;176:103745.
91. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib doi: 10.1016/j.critrevonc.2022.103745
on overall survival in patients with advanced non-small-
cell lung cancer harbouring ALK gene rearrangement: A 102. Bungaro M, Garbo E. NTRK1/2/3: Biology, detection and
retrospective analysis. Lancet Oncol. 2011;12:1004-1012. therapy. Precision Cancer Med. 2024;6.
doi: 10.1016/S1470-2045(11)70232-7 103. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of
selpercatinib in RET-altered thyroid cancers. N Engl J Med.
92. Adamo P, Ladomery M. The oncogene ERG: A key factor in 2020;383(9):825-835.
prostate cancer. Oncogene. 2016;35:403-414.
doi: 10.1056/NEJMoa2005651
doi: 10.1038/onc.2015.109
104. Houghton PJ. Advances in the treatment of BRAF-mutant
93. Hehlmann R. Chronic myeloid leukemia in 2020. low-grade glioma with MAPK inhibitors. Transl Pediatr.
Hemasphere. 2020;4(5):e468. 2024;13(3):513.
doi: 10.1097/HS9.0000000000000468 doi: 10.21037/tp-23-541
94. Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, 105. Antar DA, Laabid K, Darfaoui M, El Omrani A,
Cervera J. Acute promyelocytic leukemia: A constellation of Khouchani, M. The role of Imatinib mesylate in the
molecular events around a single PML-RARA fusion gene. treatment of metastatic dermatofibrosarcoma protuberans:
Cancers (Basel). 2020;12(3):624. A case report and literature review. Sch J Med Case Rep.
doi: 10.3390/cancers12030624 2023;6:1219-1223.
95. García-García L, Fernández-Tabanera E, Cervera ST, et al. 106. Goktas E, Sanal S, Tekinalp A. Blastoid variant mantle
The transcription factor FEZF1, a direct target of EWSR1- cell lymphoma with amplified IGH/CCND1 fusion: A
FLI1 in Ewing sarcoma cells, regulates the expression of unique case and current literature review. Med Bull Haseki.
neural-specific genes. Cancers (Basel). 2021;13(22):5668. 2024;62(2):124-127.
doi: 10.3390/cancers13225668 doi: 10.4274/haseki.galenos.2024.9567
96. Zaborowski M, Vargas AC, Pulvers J, et al. When used 107. George N, Agarwal A. 25 Genetic landscape and molecular
together SS18-SSX fusion‐specific and SSX C‐terminus mechanisms in thyroid cancer. In: Textbook of Endocrine
immunohistochemistry are highly specific and sensitive Surgery. California: Saunders; 2022: p. 216.
for the diagnosis of synovial sarcoma and can replace 108. King G, Javle M. FGFR inhibitors: clinical activity and
FISH or molecular testing in most cases. Histopathology. development in the treatment of cholangiocarcinoma. Curr
2020;77(4):588-600. Oncol Rep. 2021;23:108.
doi: 10.1111/his.14190 doi: 10.1007/s11912-021-01100-3
97. Elliott J, Bai Z, Hsieh SC, et al. ALK inhibitors for non-small 109. Li H, Wang Q. Chimeric RNAs and their implication in
cell lung cancer: A systematic review and network meta- prostate cancer. Cancer Pathog Ther. 2023;1(3):216-219.
analysis. PLoS One. 2020;15(2):e0229179.
doi: 10.1016/j.cpt.2023.04.003
doi: 10.1371/journal.pone.0229179
110. Jackson AL, Linsley PS. Recognizing and avoiding siRNA
98. Stopsack KH, Su XA, Vaselkiv JB, et al. Transcriptomes of off-target effects for target identification and therapeutic
prostate cancer with TMPRSS2: ERG and other ETS fusions. application. Nat Rev Drug Discov. 2010;9(1):57-67.
Mol Can Res. 2023;1(1):14-23.
doi: 10.1038/nrd3010
doi: 10.1158/1541-7786.MCR-22-0446
111. Mahmoudian-Sani MR, Jalali A, Jamshidi M, et al. Long
99. Østergaard A, Fiocco M, De Groot-Kruseman H, et al. non-coding RNAs in thyroid cancer: Implications for
ETV6: RUNX1 Acute Lymphoblastic Leukemia: How much pathogenesis, diagnosis, and therapy. Oncol Res Treat.
therapy is needed for cure? Leukemia. 2024;38:1-11. 2019;42(3):136-142.
doi: 10.1038/s41375-024-02287-7 doi: 10.1159/000495151

Volume 4 Issue 1 (2025) 17 doi: 10.36922/gpd.3641